ID   HT-1080/hCLDN-1
AC   CVCL_C3V7
SY   hCLDN-1/HT1080
DR   Wikidata; Q116049506
RX   PubMed=25118216;
RX   PubMed=27713828;
CC   Population: Caucasian.
CC   Sequence variation: Gene deletion; HGNC; HGNC:1787; CDKN2A; Zygosity=Homozygous (from parent cell line).
CC   Sequence variation: Mutation; HGNC; HGNC:5382; IDH1; Simple; p.Arg132Cys (c.394C>T); ClinVar=VCV000375891; Zygosity=Heterozygous (from parent cell line).
CC   Sequence variation: Mutation; HGNC; HGNC:7989; NRAS; Simple; p.Gln61Lys (c.181C>A); ClinVar=VCV000073058; Zygosity=Heterozygous (from parent cell line).
CC   Genetic integration: Method=Transfection/transduction; Gene=HGNC; HGNC:2032; CLDN1.
CC   Genetic integration: Method=Transfection/transduction; Gene=UniProtKB; P00552; Klebsiella pneumoniae transposon Tn5 neo.
CC   Derived from site: In situ; Bone, pelvis, acetabulum; UBERON=UBERON_0001269.
DI   NCIt; C3043; Fibrosarcoma
DI   ORDO; Orphanet_2030; Fibrosarcoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
HI   CVCL_0317 ! HT-1080
SX   Male
AG   35Y
CA   Cancer cell line
DT   Created: 15-12-22; Last updated: 14-08-25; Version: 6
//
RX   PubMed=27713828; DOI=10.1002/prp2.266; PMCID=PMC5045943;
RA   Hashimoto, Yosuke
RA   Kawahigashi, Yumi
RA   Hata, Tomoyuki
RA   Li, Xiang-Ru
RA   Watari, Akihiro
RA   Tada, Minoru
RA   Ishii-Watabe, Akiko
RA   Okada, Yoshiaki
RA   Doi, Takefumi
RA   Fukasawa, Masayoshi
RA   Kuniyasu, Hiroki
RA   Yagi, Kiyohito
RA   Kondoh, Masuo
RT   "Efficacy and safety evaluation of claudin-4-targeted antitumor
RT   therapy using a human and mouse cross-reactive monoclonal antibody.";
RL   Pharmacol. Res. Perspect. 4:e00266.1-e00266.14(2016).
//
RX   PubMed=25118216; DOI=10.1124/jpet.114.216911;
RA   Li, Xiang-Ru
RA   Iida, Manami
RA   Tada, Minoru
RA   Watari, Akihiro
RA   Kawahigashi, Yumi
RA   Kimura, Yuka
RA   Yamashita, Taku
RA   Ishii-Watabe, Akiko
RA   Uno, Tadayuki
RA   Fukasawa, Masayoshi
RA   Kuniyasu, Hiroki
RA   Yagi, Kiyohito
RA   Kondoh, Masuo
RT   "Development of an anti-claudin-3 and -4 bispecific monoclonal
RT   antibody for cancer diagnosis and therapy.";
RL   J. Pharmacol. Exp. Ther. 351:206-213(2014).
//